Concourse Financial Group Securities, Inc. Delcath Systems, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$7.36 - $11.0 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$4.47 - $8.37 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$3.72 - $5.09 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$2.25 - $4.17 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$3.12 - $5.85 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$3.12 - $5.85 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$5.38 - $7.96 $0 - $0
Q1 2023 May 15, 2023	BUY	$3.46 - $6.0 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.59 - $3.71 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.1 - $4.8 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.62 - $6.55 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.64 - $7.95 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$7.2 - $11.72 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$8.44 - $12.65 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$9.54 - $15.1 $0 - $0
Q1 2021 May 13, 2021	BUY	$12.42 - $23.81 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$10.55 - $18.69 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$8.8 - $12.84 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$7.31 - $13.0 $0 - $0

Others Institutions Holding DCTH

# of Institutions

Shares Held

7.62M

Call Options Held

198K

Put Options Held

41.7K

Aigh Capital Management LLC Baltimore, MD

1.78M
Shares

$17.4 Million
6.51% of portfolio
Vanguard Group Inc Valley Forge, PA

1.11M
Shares

$10.8 Million
0.0% of portfolio
Vivo Capital, LLC Palo Alto, CA

997K
Shares

$9.73 Million
1.32% of portfolio
Essex Investment Management CO LLC Boston, MA

337K
Shares

$3.29 Million
0.57% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

312K
Shares

$3.04 Million
0.0% of portfolio

View Full List

About DELCATH SYSTEMS, INC.

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $83.9M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

More about DCTH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account